Aging-US

In this top-performing research perspective published by Aging on February 12, 2021, entitled, “DNA- and telomere-damage does not limit lifespan: evidence from rapamycin,” Dr. Mikhail Blagosklonny — an adjunct faculty member at Roswell Park Comprehensive Cancer Center and the Editor-in-Chief of Aging, Oncotarget, Oncoscience, and Cell Cycle — gleaned an important new perspective from recent aging studies, which some may have overlooked.

Rapamycin is a macrolide antibiotic that has immunosuppressive properties, regulates a key cellular growth pathway (mTOR), and has been at the center of numerous studies of aging since it’s discovery in 1964. Dr. Blagosklonny explains that, based on findings from recent mouse-model studies of rapamycin’s effects on short-lived mice, normal aging is not caused by the accumulation of molecular damage or telomere shortening.

“Here I discussed new evidence that normal aging is not caused by accumulation of molecular damage or telomere shortening: while extending normal lifespan in mice, rapamycin failed to do so in mice dying from molecular damage (Figure 1).”

To date, this research paper has generated an Altmetric Attention score of 43. Altmetric Attention scores, located at the top-left of trending Aging papers, provide an at-a-glance indication of the volume and type of online attention the research has received.

Top Aging publications rated by Altmetric score: https://www.aging-us.com/news_room/altmetric

DOI - https://doi.org/10.18632/aging.202674

Full text - https://www.aging-us.com/article/202674/text

Correspondence to: Mikhail V. Blagosklonny email: [email protected]

Keywords: quasi-programmed aging, hyperfunction theory, antagonistic pleiotropy, natural selection, mTOR, rapamycin

About Aging

Launched in 2009, Aging publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ or connect with us on:

Twitter - https://twitter.com/AgingJrnl​

Facebook - https://www.facebook.com/AgingUS/​

SoundCloud - https://soundcloud.com/aging-us​

YouTube - https://www.youtube.com/agingus​

LinkedIn - https://www.linkedin.com/company/aging​

Aging is published by Impact Journals, LLC please visit http://www.ImpactJournals.com​​ or connect with @ImpactJrnls

Media Contact

18009220957

In this trending paper published in Aging on February 11, 2021, entitled, “Examining sleep deficiency and disturbance and their risk for incident dementia and all-cause mortality in older adults across 5 years in the United States,” a team of researchers from Brigham and Women’s Hospital, Harvard Medical School, and Boston College, organized a single examination of the relationships between a comprehensive set of sleep characteristics and incident dementia and all-cause mortality.

The researchers collected their baseline data from the National Health and Aging Trends Study (NHATS), which is a nationally-representative longitudinal study of Medicare beneficiaries (65 years and older) in the United States. The data were collected from a randomly selected subset of 2,812 participants from the NHATS population that were administered sleep questionnaires in 2013 and 2014.

“Participants with dementia at baseline (year 2013) were excluded (n = 202) for a sample of 2,812 with sleep data in either 2013 or 2014.”

To date, this research paper has generated an Altmetric Attention Score of 91. Altmetric Attention Scores, located at the top-left of trending Aging papers, provide an at-a-glance indication of the volume and type of online attention the research has received.

Top Aging publications rated by Altmetric Attention Score: https://www.aging-us.com/news_room/altmetric

DOI - https://doi.org/10.18632/aging.202591

Full Text - https://www.aging-us.com/article/202591/text#fulltext

Correspondence to: Rebecca Robbins email: [email protected]

Keywords: Alzheimer's Disease, Sleep, Longevity, Preventative Health Care, Aging

About Aging

Launched in 2009, Aging publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ or connect with us on:

Twitter - https://twitter.com/AgingJrnl​

Facebook - https://www.facebook.com/AgingUS/​

SoundCloud - https://soundcloud.com/aging-us​

YouTube - https://www.youtube.com/agingus​

LinkedIn - https://www.linkedin.com/company/aging​

Aging is published by Impact Journals, LLC please visit http://www.ImpactJournals.com​​ or connect with @ImpactJrnls

Media Contact

18009220957

Aging is indexed by PubMed/Medline abbreviated as “Aging (Albany NY)”, PubMed Central, ISI/Web of Science: Science Citation Index Expanded (abbreviated as Aging‑US and listed in the Cell Biology category; since June 2017 it has also been listed in the Geriatrics & Gerontology category), and Scopus /Rank Q1 (abbreviated as Aging).

Every year, the American Association for Cancer Research (AACR) organizes a conference program that covers the latest discoveries in cancer research. Topics include population science and prevention, cancer biology, translational and clinical studies, survivorship, and advocacy. This conference aims to highlight work from the best minds in research and medicine from institutions all over the world. The journal Aging, by Impact Journals, will be participating at the AACR Annual Meeting this year.

Visit Aging website: https://www.aging-us.com/

Impact Journals is an open-access publisher of rigorously peer-reviewed scientific literature, and owns several medical research journals, including Aging. Aging was launched by Impact Journals in 2009 with the goal of spotlighting high-impact papers, authored by scientists who study the process of aging and age-related diseases—including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome.

Visit Impact Journals website: https://www.impactjournals.com/

Aging has published outstanding papers and reviews by highly-cited authors and award winners, including Andrew V. Schally (Nobel Laureate), Shinya Yamanaka (Nobel Laureate), Lawrence Donehower, Toren Finkel, Stephen Helfand, Gerald Shadel, Andre Nussenzweig, Maurice Burg, Karen Vousden, Leonard Guarente, and Dale Bredesen. Importantly, the Aging Editorial Board also comprises numerous prestigious award winners, including Nobel Laureate Elizabeth H. Blackburn, and many other distinguished scientists, including Cynthia Kenyon, Judith Campisi, Leonard Guarente, Michael Hall, Mikhail Blagosklonny, Vera Gorbunova, David Sinclair, Jan Vijg, and Thomas Rando.

The journal has recently concluded its 12th year of publishing and has become Impact Journals’ featured journal. Learn more about Aging and Impact Journals at the virtual 2021 AACR conference on April 10-15 and May 17-21, 2021. Registration will be open through the beginning of the event.

More About Aging

Launched in 2009, Aging publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​ or connect with us on:

SoundCloud - https://soundcloud.com/aging-us

Twitter - https://twitter.com/AgingJrnl

Facebook - https://www.facebook.com/AgingUS/

YouTube - https://www.youtube.com/agingus

LinkedIn - https://www.linkedin.com/company/aging

Aging is published by Impact Journals, LLC please visit http://www.ImpactJournals.com​ or connect with @ImpactJrnls

Media Contact

18009220957

Aging-US recently published "From Causes of Aging to Death from COVID-19" by Blagosklonny et al. which reported that COVID-19 is not deadly early in life, but mortality increases exponentially with age - which is the strongest predictor of mortality.

The Review covers:

Age

Age-related diseases

Male Gender

Mortality from aging compared with COVID-19 mortality

Age-related diseases

Cytokine storm as a hyperfunction

Hyperfunction theory of quasi-programmed aging

Covid-19 vulnerability as an age-related syndrome

Inflamm-aging and immunosenescence

Cellular senescence as a continuation of growth

Figuratively, rapamycin rejuvenates immunity

Anti-aging medicine

Rapamycin and everolimus as anti-aging drugs and,

Potential applications of rapamycin/everolimus to COVID-19

The author contends that at its deepest level, aging is driven by inappropriately high cellular functioning. The hyperfunction theory of quasi-programmed aging explains why COVID-19 vulnerability is an age-dependent syndrome, linking it to other age-related diseases.

These conditions are typical age-related diseases: hypertension, diabetes, obesity, ischemic heart disease, chronic obstructive pulmonary disease, and other diseases.

This is because pre-existing conditions are manifestations of biological age, ultimately meaning that A. aging and B. diseases are two sides of the same coin.

The Blagosklonny Research Team goes on to highlight that an anti-aging intervention, such as rapamycin, may slow aging and age-related diseases, potentially decreasing COVID-19 vulnerability.

The Aging-US Review also reported that as soon as the COVID-19 epidemic started, it became clear that COVID-19 vulnerability is an aging-dependent condition, and the use of rapamycin was immediately suggested by independent researchers.

By decreasing biological age and preventing age-related diseases, long-term rapamycin therapy may, in theory, decrease the COVID-19 mortality rate in the elderly.

As specifically discussed in the Review section titled “Figuratively, rapamycin rejuvenates immunity”, mTOR inhibitors can improve immunity to viral infections, improve immunization and vaccination to some viruses such as the flu.

The hypothetical graph in the absence of COVID-19. COVID-19 vulnerability increases exponentially with age.

Then as discussed in the section “Cytokine storm is a hyperfunction”, cytokine storm and hyper-inflammation is the main cause of death in COVID-19 pneumonia Rapamycin, an anti-inflammatory agent, inhibits hyper-functions, cellular senescence and decrease secretion of cytokines.

DOI - https://doi.org/10.18632/aging.103493

Full text - https://www.aging-us.com/article/103493/text#fulltext

Correspondence to - Mikhail V. Blagosklonny [email protected] or [email protected]

Keywords - aging, mTOR, rapalogs, senolytics, SARS-CoV-2, COVID-19, coronavirus

Roundtable discussion involving Dr. Yunsung Lee, Dr. Anil P.S. Ori, Dr. Ake T. Lu, and Dr. Steve Horvath talking about the connections between Dr. Horvath's two papers submitted to the Journal Aging-US “Epigenome-wide association study of leukocyte telomere length” and “DNA methylation-based estimator of telomere length”

"Epigenome-wide association study of leukocyte telomere length"

Full text - https://www.aging-us.com/article/102230/text

Press release - https://www.aging-us.com/news_room/epigenome-wide-association-study-of-leukocyte-telomere-length

"DNA methylation-based estimator of telomere length" -

Full text - https://www.aging-us.com/article/102173/text

Press release - https://www.aging-us.com/news_room/dna-methylation-based-estimator-of-telomere-length

Priority Research Paper Volume 6, Issue 9 pp 707—717

Article has an altmetric score of 351

Reversal of cognitive decline: A novel therapeutic program

Dale E. Bredesen 1, 2

1 Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California, Los Angeles, CA 90095;

2 Buck Institute for Research on Aging, Novato, CA 94945

received: September 15, 2014 ; accepted: September 26, 2014 ; published: September 27, 2014

https://doi.org/10.18632/aging.100690

Editorial Volume 10, Issue 2 pp 154—155

Glioblastoma in older adults - http://www.aging-us.com/article/101377/text

Matthias Holdhoff 1, 2 , Raphael Rothenberger 2 , Ilene E. Browner 2

1 Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

2 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

received: January 11, 2018 ; published: February 1, 2018

https://doi.org/10.18632/aging.101377

Copyright: Holdhoff et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CORRESPONDING AUTHOR

Matthias Holdhoff

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License (CC BY 3.0).

Editorial Volume 10, Issue 2 pp 164—165

Ketogenic diet in cancer therapy

Daniela D. Weber 1 , Sepideh Aminazdeh-Gohari 1 , Barbara Kofler 1

1 Research Program for Receptor Biochemistry and Tumor Metabolism, University Hospital for Pediatrics of the Paracelsus Medical University, Salzburg 5020, Austria

received: January 31, 2018 ; published: February 11, 2018

https://doi.org/10.18632/aging.101382

Website - http://www.aging-us.com

Twitter - https://twitter.com/AgingJrnl

Facebook - https://www.facebook.com/AgingJrnl/

LinkedIn - https://www.linkedin.com/company/aging/

YouTube - https://www.youtube.com/channel/UCl1sAl09jJinuCBIU8tTHWA?reload=9